Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma
Cells · 27.04.2026 · 15 (9) · 794
DOI: 10.3390/cells15090794 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 27.04.2026. Verfasst von Nawar Maher und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Alessandria and Novara, Italy. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphoma, Large B-Cell, Diffuse, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Università degli Studi del Piemonte Orientale "Amedeo Avogadro", Italian Ministry of Health.
Abstract (Originalsprache)
CD20 × CD3 bispecific antibodies (BsAbs) have emerged as a meaningful therapeutic option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), redirecting endogenous T cells against malignant B cells independently of major histocompatibility complex-mediated antigen presentation, and have received regulatory approval after at least two prior lines of therapy. However, a substantial proportion of patients experience primary resistance or early relapse, underscoring the need to characterize the underlying biological mechanisms, which are the focus of this review. Several tumor-intrinsic determinants of resistance have been identified, including CD20 loss driven by MS4A1 mutations, alternative splicing, and gene deletion, as well as genomic reprogramming involving TP53, MYC, and NOTCH1 alterations. T-cell dysfunction represents another critical resistance domain, encompassing inadequate intratumoral cytotoxic CD8+ T-cell infiltration, expansion of immunosuppressive regulatory and follicular helper T cells, progressive exhaustion with upregulation of PD-1, LAG-3, TIM-3, and TIGIT, and impaired T-cell fitness from prior treatment exposure. Microenvironmental barriers, including checkpoint ligand upregulation, PD-L1-enriched extracellular vesicles, spatial exclusion of effector cells from immune-cold germinal center-like niches, hypoxia, and metabolic competition, further reinforce immune escape. Emerging strategies to overcome resistance include epigenetic priming, checkpoint inhibitor combinations, 4-1BB costimulatory approaches, and next-generation multispecific antibody designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Alessandria and Novara, Italy.
ORCID-Profile: Nawar Maher, Bashar Al Deeban, Ndeye Marie Diop, Samir Mouhssine, Gianluca Gaidano
Förderung
- Italian Association for Cancer Research
- Università degli Studi del Piemonte Orientale "Amedeo Avogadro"
- Italian Ministry of Health
- AIL Novara VCO ODV
- Molecular Bases of Disease Dissemination in Lymphoid Malignancies to Optimize Curative Ther-apeutic Strategies
- the AGING Project—Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy
- Italian MoH
Zitieren
APA
Maher, N., Al Deeban, B., Diop, N. M., Assaf, J., Moia, R., Mouhssine, S., & Gaidano, G. (2026). Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. Cells, 15(9), 794. https://doi.org/10.3390/cells15090794
Vancouver
Maher N, Al Deeban B, Diop NM, Assaf J, Moia R, Mouhssine S, et al. Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. Cells. 2026;15(9):794. doi:10.3390/cells15090794
BibTeX
@article{Maher2026,
author = {Maher, Nawar and Al Deeban, Bashar and Diop, Ndeye Marie and Assaf, Joelle and Moia, Riccardo and Mouhssine, Samir and Gaidano, Gianluca},
title = {Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma},
journal = {Cells},
year = {2026},
volume = {15},
number = {9},
pages = {794},
doi = {10.3390/cells15090794}
}
EUVIMED